Advertisement

Complementation of Pharmacogenetics with Biomarkers and Neuroimaging in Major Depression

  • Andreas MenkeEmail author
  • Nicola Dusi
  • Paolo Brambilla
Chapter

Abstract

Unlike other disciplines of medicine, the diagnostic process in psychiatry is based solely on clinical judgment, without incorporating lab-derived objective measures on a regular basis. Even with the advent of DMS-V, no biomarkers gathered from genomics, peripheral blood, or brain imaging have been established for the diagnostic process in psychiatric disorders. However, there is accumulating evidence of evolving biomarkers to improve diagnostic processes and treatment algorithm. Here, studies on the evaluation of markers derived from imaging and peripheral blood in patients with major depression are reviewed. An altered brain network that encompasses the anterior cingulate, the prefrontal cortex, and the hippocampus has been repeatedly found in major depression. Antidepressants exert neuroprotective effects, which determine a reduction of hippocampal and prefrontal cortex shrinkage, probably through an activation of neuromodulatory factors like BDNF. Lower BDNF plasma levels are observed in depressed patients and normalize after successful treatment. Very promising findings have also been observed within inflammatory pathways and the hypothalamic–pituitary–adrenal (HPA) axis. In both systems, there is growing evidence that drugs specifically targeting these systems may be beneficial for the treatment of depression, but only in these patients, who have marked alterations detected by the respective biomarkers.

Keywords

Glucocorticoid Receptor Depressed Patient Hippocampal Volume Plasma Vascular Endothelial Growth Factor Level Total Reactive Antioxidant Potential 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

PB was partially supported by grants from the Italian Ministry of Health (RF‐2011‐02352308), the BIAL Foundation (Fellowship#262/12), and the IRCCS “E. Medea” (Ricerca Corrente).

AM inventor: Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (TESI). European patent number: 2166112. International application number: PCT/EP2009/061575.

References

  1. 1.
    Arnone D, McIntosh AM, Ebmeier KP, Munafo MR, Anderson IM (2012) Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. Eur Neuropsychopharmacol 22(1):1–16. doi: 10.1016/j.euroneuro.2011.05.003 CrossRefPubMedGoogle Scholar
  2. 2.
    Aschbacher K, Mills PJ, von Kanel R, Hong S, Mausbach BT, Roepke SK, Dimsdale JE, Patterson TL, Ziegler MG, Ancoli-Israel S, Grant I (2008) Effects of depressive and anxious symptoms on norepinephrine and platelet P-selectin responses to acute psychological stress among elderly caregivers. Brain Behav Immun 22(4):493–502. doi: 10.1016/j.bbi.2007.10.002 PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Aubry JM N, Osiek C, Perret G, Rossier MF, Bertschy G, Bondolfi G (2007) The DEX/CRH neuroendocrine test and the prediction of depressive relapse in remitted depressed outpatients. J Psychiatr Res 41(3–4):290–294. doi: 10.1016/j.jpsychires.2006.07.007, S0022-3956(06)00143-9 [pii]CrossRefPubMedGoogle Scholar
  4. 4.
    Barron E, Lara J, White M, Mathers JC (2015) Blood-borne biomarkers of mortality risk: systematic review of cohort studies. PLoS One 10(6):e0127550. doi: 10.1371/journal.pone.0127550 PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Bearden CE, Thompson PM, Avedissian C, Klunder AD, Nicoletti M, Dierschke N, Brambilla P, Soares JC (2009) Altered hippocampal morphology in unmedicated patients with major depressive illness. ASN Neuro 1(4). doi:AN20090026 [pii]  10.1042/AN20090026
  6. 6.
    Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF (2002) An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 52(5):386–392CrossRefPubMedGoogle Scholar
  7. 7.
    Bellani M, Dusi N, Brambilla P (2010) Longitudinal imaging studies in schizophrenia: the relationship between brain morphology and outcome measures. Epidemiol Psichiatr Soc 19(3):207–210PubMedGoogle Scholar
  8. 8.
    Bellani M, Dusi N, Brambilla P (2013) Can brain imaging address psychosocial functioning and outcome in schizophrenia? In: Thornicroft G, Ruggeri M, Goldberg D (eds) Improving mental health care: the global challenge. Wiley-Blackwell, pp 281–290Google Scholar
  9. 9.
    Bellani M, Dusi N, Yeh PH, Soares JC, Brambilla P (2011) The effects of antidepressants on human brain as detected by imaging studies. Focus on major depression. Prog Neuropsychopharmacol Biol Psychiatry 35(7):1544–1552. doi: 10.1016/j.pnpbp.2010.11.040 CrossRefPubMedGoogle Scholar
  10. 10.
    Binder EB (2009) The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34(Suppl 1):186–195. doi: 10.1016/j.psyneuen.2009.05.021, S0306-4530(09)00185-1 [pii]CrossRefGoogle Scholar
  11. 11.
    Brambilla P, Nicoletti MA, Harenski K, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC (2002) Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar subjects. Neuropsychopharmacology 27(5):792–799. doi: 10.1016/S0893–133X(02)00352–4 CrossRefPubMedGoogle Scholar
  12. 12.
    Brambilla P, Perlini C, Rajagopalan P, Saharan P, Rambaldelli G, Bellani M, Dusi N, Cerini R, Pozzi Mucelli R, Tansella M, Thompson PM (2013) Schizophrenia severity, social functioning and hippocampal neuroanatomy: three-dimensional mapping study. Br J Psychiatry 202(1):50–55. doi: 10.1192/bjp.bp.111.105700 PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Campbell S, Marriott M, Nahmias C, MacQueen GM (2004) Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 161(4):598–607CrossRefPubMedGoogle Scholar
  14. 14.
    Carpenter LL, Ross NS, Tyrka AR, Anderson GM, Kelly M, Price LH (2009) Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. Psychoneuroendocrinology 34(8):1208–1213. doi: 10.1016/j.psyneuen.2009.03.009, S0306–4530(09)00092–4 [pii]PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Carroll BJ, Curtis GC, Mendels J (1976) Neuroendocrine regulation in depression. II. Discrimination of depressed from nondepressed patients. Arch Gen Psychiatry 33(9):1051–1058Google Scholar
  16. 16.
    Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M (2010) Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int J Neuropsychopharmacol 13(1):103–108. doi: 10.1017/S1461145709990812, S1461145709990812 [pii]CrossRefPubMedGoogle Scholar
  17. 17.
    Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM (2013) Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology 38(3):377–385. doi: 10.1038/npp.2012.191, npp2012191 [pii]PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Cattaneo A, Sesta A, Calabrese F, Nielsen G, Riva MA, Gennarelli M (2013) The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology 35(7):1423–1428. doi: 10.1038/npp.2010.11, npp201011 [pii]CrossRefGoogle Scholar
  19. 19.
    Chen CH, Ridler K, Suckling J, Williams S, Fu CH, Merlo-Pich E, Bullmore E (2007) Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biological psychiatry 62(5):407–414. doi: 10.1016/j.biopsych.2006.09.018 Google Scholar
  20. 20.
    Clark-Raymond A, Meresh E, Hoppensteadt D, Fareed J, Sinacore J, Halaris A (2014) Vascular Endothelial Growth Factor: a potential diagnostic biomarker for major depression. J Psychiatr Res 59:22–27. doi: 10.1016/j.jpsychires.2014.08.005 CrossRefPubMedGoogle Scholar
  21. 21.
    Cole J, Costafreda SG, McGuffin P, Fu CH (2011) Hippocampal atrophy in first episode depression: a meta-analysis of magnetic resonance imaging studies. J Affect Disord 134(1–3):483–487. doi: 10.1016/j.jad.2011.05.057 CrossRefPubMedGoogle Scholar
  22. 22.
    Colla M, Kronenberg G, Deuschle M, Meichel K, Hagen T, Bohrer M, Heuser I (2007) Hippocampal volume reduction and HPA-system activity in major depression. J Psychiatr Res 41(7):553–560. doi: 10.1016/j.jpsychires.2006.06.011 CrossRefPubMedGoogle Scholar
  23. 23.
    Coryell W, Schlesser M (2001) The dexamethasone suppression test and suicide prediction. Am J Psychiatry 158(5):748–753.Google Scholar
  24. 24.
    Costafreda SG, Chu C, Ashburner J, Fu CH (2009) Prognostic and diagnostic potential of the structural neuroanatomy of depression. PloS one 4(7):e6353. doi: 10.1371/journal.pone.0006353 Google Scholar
  25. 25.
    Dusi N, Perlini C, Bellani M, Brambilla P (2012) Searching for psychosocial endophenotypes in schizophrenia: the innovative role of brain imaging. Riv Psichiatr 47(2):76–88. doi: 10.1708/1069.11712 PubMedGoogle Scholar
  26. 26.
    Fernandes BS, Berk M, Turck CW, Steiner J, Goncalves CA (2014) Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry 19(7):750–751. doi: 10.1038/mp.2013.172 CrossRefPubMedGoogle Scholar
  27. 27.
    Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF (2006) Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31(3):628–636. doi: 10.1038/sj.npp.1300884 CrossRefPubMedGoogle Scholar
  28. 28.
    Frodl T, Meisenzahl EM, Zetzsche T, Hohne T, Banac S, Schorr C, Jager M, Leinsinger G, Bottlender R, Reiser M, Moller HJ (2004) Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. The Journal of clinical psychiatry 65(4):492–499Google Scholar
  29. 29.
    Frodl TS, Koutsouleris N, Bottlender R, Born C, Jager M, Scupin I, Reiser M, Moller HJ, Meisenzahl EM (2008) Depression-related variation in brain morphology over 3 years: effects of stress? Arch Gen Psychiatry 65(10):1156–1165. doi: 10.1001/archpsyc.65.10.1156 CrossRefPubMedGoogle Scholar
  30. 30.
    Fu C, Costafreda S, Sankar A, Adams T, Rasenick M, Liu P, Donati R, Maglanoc L, Horton P, Marangell L (2015) Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine. BMC Psychiatry 15(1):82PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Gaali S, Kirschner A, Cuboni S, Hartmann J, Kozany C, Balsevich G, Namendorf C, Fernandez-Vizarra P, Sippel C, Zannas AS, Draenert R, Binder EB, Almeida OF, Ruhter G, Uhr M, Schmidt MV, Touma C, Bracher A, Hausch F (2015) Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat Chem Biol 11(1):33–37. doi: 10.1038/nchembio.1699 CrossRefPubMedGoogle Scholar
  32. 32.
    Galfalvy H, Currier D, Oquendo MA, Sullivan G, Huang YY, John Mann J (2009) Lower CSF MHPG predicts short-term risk for suicide attempt. Int J Neuropsychopharmacol 12(10):1327–1335. doi: 10.1017/S1461145709990228 PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Gallagher P, Malik N, Newham J, Young AH, Ferrier IN, Mackin P (2015) WITHDRAWN: Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev 6:CD005168. doi: 10.1002/14651858.CD005168.pub3
  34. 34.
    Gold PW (2015) The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry 20(1):32–47. doi: 10.1038/mp.2014.163 CrossRefPubMedGoogle Scholar
  35. 35.
    Gunning FM, Cheng J, Murphy CF, Kanellopoulos D, Acuna J, Hoptman MJ, Klimstra S, Morimoto S, Weinberg J, Alexopoulos GS (2009) Anterior cingulate cortical volumes and treatment remission of geriatric depression. International Journal of Geriatric Psychiatry 24(8):829–836. doi: 10.1002/gps.2290 Google Scholar
  36. 36.
    Gunning-Dixon FM, Walton M, Cheng J, Acuna J, Klimstra S, Zimmerman ME, Brickman AM, Hoptman MJ, Young RC, Alexopoulos GS (2010) MRI signal hyperintensities and treatment remission of geriatric depression. Journal of Affective Disorders 126(3):395–401. doi:http://dx.doi.org/10.1016/j.jad.2010.04.004 Google Scholar
  37. 37.
    Halmai Z, Dome P, Dobos J, Gonda X, Szekely A, Sasvari-Szekely M, Faludi G, Lazary J (2013) Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: results of a preliminary study. J Affect Disord 144(3):269–273. doi: 10.1016/j.jad.2012.09.006 CrossRefPubMedGoogle Scholar
  38. 38.
    Harley J, Luty S, Carter J, Mulder R, Joyce P (2010) Elevated C-reactive protein in depression: a predictor of good long-term outcome with antidepressants and poor outcome with psychotherapy. J Psychopharmacol 24(4):625–626. doi: 10.1177/0269881109102770 CrossRefPubMedGoogle Scholar
  39. 39.
    Hastings RS, Parsey RV, Oquendo MA, Arango V, Mann JJ (2004) Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacology 29(5):952–959. doi: 10.1038/sj.npp.1300371 CrossRefPubMedGoogle Scholar
  40. 40.
    Hennings JM, Uhr M, Klengel T, Weber P, Putz B, Touma C, Czamara D, Ising M, Holsboer F, Lucae S (2015) RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. Transcult Psychiatry 5:e538. doi: 10.1038/tp.2015.9 CrossRefGoogle Scholar
  41. 41.
    Heuser I, Yassouridis A, Holsboer F (1994) The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28(4):341–356CrossRefPubMedGoogle Scholar
  42. 42.
    Himmerich H, Fulda S, Sheldrick AJ, Plumakers B, Rink L (2010) IFN-gamma reduction by tricyclic antidepressants. Int J Psychiatry Med 40(4):413–424CrossRefPubMedGoogle Scholar
  43. 43.
    Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23(5):477–501CrossRefPubMedGoogle Scholar
  44. 44.
    Hsieh MH, McQuoid DR, Levy RM, Payne ME, MacFall JR, Steffens DC (2002) Hippocampal volume and antidepressant response in geriatric depression. International Journal of Geriatric Psychiatry 17(6):519–525. doi: 10.1002/gps.611 Google Scholar
  45. 45.
    Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N, Kunzel HE, Pfennig A, Uhr M, Holsboer F (2007) Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression – a potential biomarker? Biol Psychiatry 62(1):47–54. doi: 10.1016/j.biopsych.2006.07.039, S0006-3223(06)01002-X [pii]CrossRefPubMedGoogle Scholar
  46. 46.
    Iyengar RL, Gandhi S, Aneja A, Thorpe K, Razzouk L, Greenberg J, Mosovich S, Farkouh ME (2013) NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med 126(11):1017 e1011–1018. doi: 10.1016/j.amjmed.2013.02.037 CrossRefGoogle Scholar
  47. 47.
    Jetten AM (2004) Recent advances in the mechanisms of action and physiological functions of the retinoid-related orphan receptors (RORs). Curr Drug Targets Inflamm Allergy 3(4):395–412CrossRefPubMedGoogle Scholar
  48. 48.
    Jung J, Kang J, Won E, Nam K, Lee M-S, Tae WS, Ham B-J (2014) Impact of lingual gyrus volume on antidepressant response and neurocognitive functions in Major Depressive Disorder: A voxel-based morphometry study. Journal of Affective Disorders 169:179–187. doi:http://dx.doi.org/10.1016/j.jad.2014.08.018 Google Scholar
  49. 49.
    Kaestner F, Hettich M, Peters M, Sibrowski W, Hetzel G, Ponath G, Arolt V, Cassens U, Rothermundt M (2005) Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J Affect Disord 87(2–3):305–311. doi: 10.1016/j.jad.2005.03.012, S0165-0327(05)00087-X [pii]CrossRefPubMedGoogle Scholar
  50. 50.
    Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant’Anna M, Klamt F, Pasquali MA, Quevedo J, Gama CS, Post R (2010) A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 15(8):784–786. doi: 10.1038/mp.2009.112 CrossRefPubMedGoogle Scholar
  51. 51.
    Katz ER, Stowe ZN, Newport DJ, Kelley ME, Pace TW, Cubells JF, Binder EB (2012) Regulation of mRNA expression encoding chaperone and co-chaperone proteins of the glucocorticoid receptor in peripheral blood: association with depressive symptoms during pregnancy. Psychol Med 42(5):943–956. doi: 10.1017/S0033291711002121, S0033291711002121 [pii]CrossRefPubMedGoogle Scholar
  52. 52.
    Klauser P, Fornito A, Lorenzetti V, Davey CG, Dwyer DB, Allen NB, Yücel M (2015) Cortico-limbic network abnormalities in individuals with current and past major depressive disorder. J Affect Disord 173(0):45–52. doi:http://dx.doi.org/10.1016/j.jad.2014.10.041 Google Scholar
  53. 53.
    Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71(12):1381–1391. doi: 10.1001/jamapsychiatry.2014.1611 CrossRefPubMedGoogle Scholar
  54. 54.
    Kong L, Wu F, Tang Y, Ren L, Kong D, Liu Y, Xu K, Wang F (2014) Frontal-subcortical volumetric deficits in single episode, medication-naive depressed patients and the effects of 8 weeks fluoxetine treatment: a VBM-DARTEL study. PLoS One 9(1):e79055. doi: 10.1371/journal.pone.0079055 PubMedCentralCrossRefPubMedGoogle Scholar
  55. 55.
    Korgaonkar MS, Rekshan W, Gordon E, Rush AJ, Williams LM, Blasey C, Grieve SM (2015) Magnetic resonance imaging measures of brain structure to predict antidepressant treatment outcome in major depressive disorder. EBioMedicine 2(1):37–45. doi: 10.1016/j.ebiom.2014.12.002 PubMedCentralCrossRefPubMedGoogle Scholar
  56. 56.
    Kronmuller KT, Pantel J, Gotz B, Kohler S, Victor D, Mundt C, Magnotta VA, Giesel F, Essig M, Schroder J (2008) Life events and hippocampal volume in first-episode major depression. J Affect Disord. 110:241–7Google Scholar
  57. 57.
    Kunugi H, Ida I, Owashi T, Kimura M, Inoue Y, Nakagawa S, Yabana T, Urushibara T, Kanai R, Aihara M, Yuuki N, Otsubo T, Oshima A, Kudo K, Inoue T, Kitaichi Y, Shirakawa O, Isogawa K, Nagayama H, Kamijima K, Nanko S, Kanba S, Higuchi T, Mikuni M (2006) Assessment of the Dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology 31(1):212–220PubMedGoogle Scholar
  58. 58.
    Lai C, Hsu, YY (2011) A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks’ duloxetine therapy. Int J Neuropsychopharmacol. 14:225–35Google Scholar
  59. 59.
    Lavretsky H, Roybal DJ, Ballmaier M, Toga AW, Kumar A (2005) Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. The Journal of Clinical Psychiatry 66(8):964–967Google Scholar
  60. 60.
    Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA (2006) The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 147:126–132CrossRefPubMedGoogle Scholar
  61. 61.
    Li C-T, Lin C-P, Chou K-H, Chen IY, Hsieh J-C, Wu C-L, Lin W-C, Su T-P (2010) Structural and cognitive deficits in remitting and non-remitting recurrent depression: A voxel-based morphometric study. NeuroImage 50(1):347–356. doi: http://dx.doi.org/10.1016/j.neuroimage.2009.11.021 Google Scholar
  62. 62.
    Liu Y, Ho RC, Mak A (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 139(3):230–239. doi: 10.1016/j.jad.2011.08.003 CrossRefPubMedGoogle Scholar
  63. 63.
    Lorenzetti V, Allen NB, Whittle S, Yücel M (2010) Amygdala volumes in a sample of current depressed and remitted depressed patients and healthy controls. Journal of Affective Disorders 120(1–3):112–119. doi:http://dx.doi.org/10.1016/j.jad.2009.04.021 Google Scholar
  64. 64.
    MacQueen GM, Yucel K, Taylor VH, Macdonald K, Joffe R (2008) Posterior Hippocampal Volumes Are Associated with Remission Rates in Patients with Major Depressive Disorder. Biological Psychiatry 64(10):880–883. doi:http://dx.doi.org/10.1016/j.biopsych.2008.06.027 Google Scholar
  65. 65.
    Matsubara T, Funato H, Kobayashi A, Nobumoto M, Watanabe Y (2006) Reduced glucocorticoid receptor alpha expression in mood disorder patients and first-degree relatives. Biol Psychiatry 59(8):689–695. doi: 10.1016/j.biopsych.2005.09.026, S0006–3223(05)01431–9 [pii]CrossRefPubMedGoogle Scholar
  66. 66.
    McEwen BS (2000) Effects of adverse experiences for brain structure and function. Biol Psychiatry 48(8):721–731CrossRefPubMedGoogle Scholar
  67. 67.
    Menke A, Arloth J, Gerber M, Rex-Haffner M, Uhr M, Holsboer F, Binder EB, Holsboer-Trachsler E, Beck J (2014) Dexamethasone stimulated gene expression in peripheral blood indicates glucocorticoid-receptor hypersensitivity in job-related exhaustion. Psychoneuroendocrinology 44:35–46. doi: 10.1016/j.psyneuen.2014.02.013, S0306–4530(14)00064-X [pii]CrossRefPubMedGoogle Scholar
  68. 68.
    Menke A, Arloth J, Putz B, Weber P, Klengel T, Mehta D, Gonik M, Rex-Haffner M, Rubel J, Uhr M, Lucae S, Deussing JM, Muller-Myhsok B, Holsboer F, Binder EB (2012) Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 37(6):1455–1464. doi: 10.1038/npp.2011.331, npp2011331 [pii]PubMedCentralCrossRefPubMedGoogle Scholar
  69. 69.
    Menke A, Klengel T, Rubel J, Bruckl T, Pfister H, Lucae S, Uhr M, Holsboer F, Binder EB (2013) Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav 12(3):289–296. doi: 10.1111/gbb.12026 CrossRefPubMedGoogle Scholar
  70. 70.
    Murphy GM Jr, Sarginson JE, Ryan HS, O’Hara R, Schatzberg AF, Lazzeroni LC (2013) BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. Pharmacogenet Genomics 23(6):301–313. doi: 10.1097/FPC.0b013e328360b175, 01213011–201306000–00002 [pii]CrossRefPubMedGoogle Scholar
  71. 71.
    Na KS, Lee KJ, Lee JS, Cho YS, Jung HY (2014) Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 48:79–85. doi: 10.1016/j.pnpbp.2013.09.006 CrossRefPubMedGoogle Scholar
  72. 72.
    Nelson JC, Davis JM (1997) DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 154(11):1497–1503. doi: 10.1038/nrcardio.2012.91 CrossRefPubMedGoogle Scholar
  73. 73.
    Neumeister A, Wood S, Bonne O, Nugent AC, Luckenbaugh DA, Young T, Bain EE, Charney DS, Drevets WC (2005) Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry 57(8):935–937. doi: 10.1016/j.biopsych.2005.01.016 CrossRefPubMedGoogle Scholar
  74. 74.
    Nierenberg AA, Feinstein AR (1988) How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test. JAMA 259(11):1699–1702CrossRefPubMedGoogle Scholar
  75. 75.
    Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri MN (2010) Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry 34(4):645–651. doi: 10.1016/j.pnpbp.2010.03.003, S0278–5846(10)00079–5 [pii]CrossRefPubMedGoogle Scholar
  76. 76.
    Pantel J, Schröder J, Essig M, Popp D, Dech H, Knopp MV, Schad LR, Eysenbach K, Backenstraβ M, Friedlinger M (1997) Quantitative magnetic resonance imaging in geriatric depression and primary degenerative dementia. J Affect Disord 42(1):69–83. doi:http://dx.doi.org/10.1016/S0165–0327(96)00105-X
  77. 77.
    Papakostas GI, Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Alpert JE, Nierenberg AA, Fava M (2005) Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiatry Research: Neuroimaging 140(3):301–307. doi:http://dx.doi.org/10.1016/j.pscychresns.2005.09.001 Google Scholar
  78. 78.
    Paslakis G, Krumm B, Gilles M, Schweiger U, Heuser I, Richter I, Deuschle M (2011) Discrimination between patients with melancholic depression and healthy controls: comparison between 24-h cortisol profiles, the DST and the Dex/CRH test. Psychoneuroendocrinology 36(5):691–698. doi: 10.1016/j.psyneuen.2010.10.002 CrossRefPubMedGoogle Scholar
  79. 79.
    Pfennig A, Kunzel HE, Kern N, Ising M, Majer M, Fuchs B, Ernst G, Holsboer F, Binder EB (2005) Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression. Biol Psychiatry 57(4):336–342CrossRefPubMedGoogle Scholar
  80. 80.
    Phillips JL, Batten LA, Tremblay P, Aldosary F, Blier P (2015) A prospective, longitudinal study of the effect of remission on cortical thickness and Hippocampal volume in patients with treatment-resistant depression. Int J Neuropsychopharmacol 18(8)Google Scholar
  81. 81.
    Pizzagalli DA, Oakes TR, Fox AS, Chung MK, Larson CL, Abercrombie HC, Schaefer SM, Benca RM, Davidson RJ (2004) Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. Molecular psychiatry 9(4):325, 393–405. doi: 10.1038/sj.mp.4001469 Google Scholar
  82. 82.
    Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70(1):31–41. doi: 10.1001/2013.jamapsychiatry.4 PubMedCentralCrossRefPubMedGoogle Scholar
  83. 83.
    Ribeiz SR, Duran F, Oliveira MC, Bezerra D, Castro CC, Steffens DC, Busatto Filho G, Bottino CM (2013) Structural brain changes as biomarkers and outcome predictors in patients with late-life depression: a cross-sectional and prospective study. PLoS One 8(11):e80049. doi: 10.1371/journal.pone.0080049 PubMedCentralCrossRefPubMedGoogle Scholar
  84. 84.
    Rupprecht R, Rupprecht M, Rupprecht C, Sofic E, Barocka A, Beck G, Noder M, Riederer P (1989) Effects of glucocorticoids on plasma catecholamines in depression. Psychiatry Res 29(2):187–198CrossRefPubMedGoogle Scholar
  85. 85.
    Rydmark I, Wahlberg K, Ghatan PH, Modell S, Nygren A, Ingvar M, Asberg M, Heilig M (2006) Neuroendocrine, cognitive and structural imaging characteristics of women on longterm sickleave with job stress-induced depression. Biol Psychiatry 60(8):867–873. doi: 10.1016/j.biopsych.2006.04.029, S0006–3223(06)00563–4 [pii]CrossRefPubMedGoogle Scholar
  86. 86.
    Salloway S, Correia S, Boyle P, Malloy P, Schneider L, Lavretsky H, Sackheim H, Roose S, Krishnan KRR (2002) MRI subcortical hyperintensities in old and very old depressed outpatients: The important role of age in late-life depression. Journal of the neurological sciences 203–204:227–233. doi:http://dx.doi.org/10.1016/S0022-510X(02)00296-4 Google Scholar
  87. 87.
    Sassi RB, Brambilla P, Nicoletti M, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC (2003) White matter hyperintensities in bipolar and unipolar patients with relatively mild-to-moderate illness severity. J Affect Disord 77(3):237–245CrossRefPubMedGoogle Scholar
  88. 88.
    Serretti A, Mandelli L, Bajo E, Cevenini N, Papili P, Mori E, Bigelli M, Berardi D (2009) The socio-economical burden of schizophrenia: a simulation of cost-offset of early intervention program in Italy. Eur Psychiatry 24(1):11–16. doi:http://dx.doi.org/10.1016/j.eurpsy.2008.07.009 Google Scholar
  89. 89.
    Sheline YI, Gado MH, Price JL (1998) Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 9(9):2023–2028CrossRefPubMedGoogle Scholar
  90. 90.
    Sheline YI, Pieper CF, Barch DM, Welsh-Bohmer K, McKinstry RC, MacFall JR, D’Angelo G, Garcia KS, Gersing K, Wilkins C, Taylor W, Steffens DC, Krishnan RR, Doraiswamy PM (2010) Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Archives of General Psychiatry 67(3):277–285. doi: 10.1001/archgenpsychiatry.2009.204 Google Scholar
  91. 91.
    Sheline YI, Disabato BM, Hranilovich J, Morris C, D’Angelo G, Pieper C, Toffanin T, Taylor WD, MacFall JR, Wilkins C, Barch DM, Welsh-Bohmer KA, Steffens DC, Krishnan RR, Doraiswamy PM (2012) Treatment course with antidepressant therapy in late-life depression. The American Journal of Psychiatry 169(11):1185–1193Google Scholar
  92. 92.
    Sher L, Oquendo MA, Burke AK, Cooper TB, Mann JJ (2013) Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers. J Affect Disord 151(3):1108–1112. doi: 10.1016/j.jad.2013.06.049, S0165–0327(13)00529–6 [pii]CrossRefPubMedGoogle Scholar
  93. 93.
    Smith R, Chen K, Baxter L, Fort C, Lane RD (2013) Antidepressant effects of sertraline associated with volume increases in dorsolateral prefrontal cortex. J Affect Disord 146(3):414–419. doi:http://dx.doi.org/10.1016/j.jad.2012.07.029 Google Scholar
  94. 94.
    Sneed JR, Culang-Reinlieb ME, Brickman AM, Gunning-Dixon FM, Johnert L, Garcon E, Roose SP (2011) MRI signal hyperintensities and failure to remit following antidepressant treatment. Journal of affective disorders 135(1–3):315–320. doi:http://dx.doi.org/10.1016/j.jad.2011.06.052 Google Scholar
  95. 95.
    Sullivan EV, Marsh L, Mathalon DH, Lim KO, Pfefferbaum A (1995) Anterior hippocampal volume deficits in nonamnesic, aging chronic alcoholics. Alcohol Clin Exp Res 19(1):110–122CrossRefPubMedGoogle Scholar
  96. 96.
    Taylor WD, Kudra K, Zhao Z, Steffens DC, MacFall JR (2014) Cingulum bundle white matter lesions influence antidepressant response in late-life depression: a pilot study. J Affect Disord 162(0):8–11. doi:http://dx.doi.org/10.1016/j.jad.2014.03.031 Google Scholar
  97. 97.
    Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, Hauser J, Maier W, Kozel D, Henigsberg N, Barreto M, Placentino A, Dernovsek MZ, Schulze TG, Kalember P, Zobel A, Czerski PM, Larsen ER, Souery D, Giovannini C, Gray JM, Lewis CM, Farmer A, Aitchison KJ, McGuffin P, Craig I (2009) Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9(4):225–233. doi: 10.1038/tpj.2009.12, tpj200912 [pii]CrossRefPubMedGoogle Scholar
  98. 98.
    Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, McGuffin P (2014) An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 171(12):1278–1286. doi: 10.1176/appi.ajp.2014.14010094 CrossRefPubMedGoogle Scholar
  99. 99.
    van Eijndhoven P, van Wingen G, Katzenbauer M, Groen W, Tepest R, Fernandez G, Buitelaar J, Tendolkar I (2013) Paralimbic cortical thickness in first-episode depression: evidence for trait-related differences in mood regulation. Am J Psychiatry 170(12):1477–1486. doi: 10.1176/appi.ajp.2013.12121504 CrossRefPubMedGoogle Scholar
  100. 100.
    Vakili K, Pillay SS, Lafer B, Fava M, Renshaw PF, Bonello-Cintron CM, Yurgelun-Todd DA (2000) Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biological psychiatry 47(12):1087–1090. doi: 10.1016/S0006-3223(99)00296-6 Google Scholar
  101. 101.
    Vythilingam M, Heim C, Newport J, Miller AH, Anderson E, Bronen R, Brummer M, Staib L, Vermetten E, Charney DS, Nemeroff CB, Bremner JD (2002) Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry 159(12):2072–2080PubMedCentralCrossRefPubMedGoogle Scholar
  102. 102.
    Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J, Staib LH, Charney DS, Bremner JD (2004) Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry 56(2):101–112. doi: 10.1016/j.biopsych.2004.04.002 CrossRefPubMedGoogle Scholar
  103. 103.
    Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P (2011) Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 108(22):9262–9267. doi: 10.1073/pnas.1104836108 PubMedCentralCrossRefPubMedGoogle Scholar
  104. 104.
    Xiong P, Zeng Y, Wu Q, Han Huang DX, Zainal H, Xu X, Wan J, Xu F, Lu J (2014) Combining serum protein concentrations to diagnose schizophrenia: a preliminary exploration. J Clin Psychiatry 75(8):e794–e801. doi: 10.4088/JCP.13m0877 CrossRefPubMedGoogle Scholar
  105. 105.
    Yuen GS, Gunning FM, Woods E, Klimstra SA, Hoptman MJ, Alexopoulos GS (2014) Neuroanatomical correlates of apathy in late-life depression and antidepressant treatment response. J Affect Disord 166(0):179–186. doi:http://dx.doi.org/10.1016/j.jad.2014.05.008 Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Psychiatry, Psychosomatics and PsychotherapyUniversity Hospital of WürzburgWürzburgGermany
  2. 2.Section of Psychiatry, Department of Public Health and Community MedicineInter-University Center for Behavioral Neurosciences (ICBN), University of VeronaVeronaItaly
  3. 3.Department of Neurosciences and Mental HealthFondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of MilanMilanItaly
  4. 4.Scientific Institute IRCCS “E. Medea”Bosisio Parini (Lc)Italy
  5. 5.Department of Psychiatry and Behavioral SciencesUniversity of Texas Health Science Center at HoustonHoustonUSA

Personalised recommendations